Mouse antibody-coated lymphocytes during OKT3 therapy in liver transplantation

T. A. Broughan, R. Valenzuela, E. Escorcia, M. Secic, D. P. Vogt

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Flow cytometry has been a technique in search of a use in transplantation. With each new monoclonal antibody, it has been hoped that the secrets of rejection would be unlocked. The usefulness of CD3+ T-lymphocyte counts to predict successful treatment of organ transplant rejection has been called into question. CD2+, CD3+, and mouse antibody-coated CD3+ lymphocytes were followed by flow cytometry in 44 liver transplant patients during OKT3 therapy for induction or rejection. CD3+ lymphocyte counts did not predict successful management of rejection by OKT3. When expressed as percentages of the total lymphocyte count, an increasing trend in CD2+ and mouse antibody-coated CD3+ lymphocytes after day 7 of OKT3 therapy portended persistent or recurrent rejection within 2 months of treatment. It is uncertain if the increasing population of mouse antibody-coated CD3 cells is due to an immune phenomen or decreased clearance by an ailing liver. Care should be taken when using CD3 lymphocyte counts as indicators of adequate OKT3 therapy in liver transplantation.

Original languageEnglish
Pages (from-to)488-491
Number of pages4
JournalClinical Transplantation
Volume8
Issue number5
StatePublished - Nov 11 1994
Externally publishedYes

Fingerprint

Muromonab-CD3
Liver Transplantation
Lymphocyte Count
Lymphocytes
Antibodies
Flow Cytometry
Transplants
Therapeutics
Liver
Graft Rejection
Transplantation
Monoclonal Antibodies
T-Lymphocytes
Population

Keywords

  • Flow cytometry
  • Liver transplantation
  • Monoclonal antibody
  • Rejection

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Cite this

Broughan, T. A., Valenzuela, R., Escorcia, E., Secic, M., & Vogt, D. P. (1994). Mouse antibody-coated lymphocytes during OKT3 therapy in liver transplantation. Clinical Transplantation, 8(5), 488-491.

Mouse antibody-coated lymphocytes during OKT3 therapy in liver transplantation. / Broughan, T. A.; Valenzuela, R.; Escorcia, E.; Secic, M.; Vogt, D. P.

In: Clinical Transplantation, Vol. 8, No. 5, 11.11.1994, p. 488-491.

Research output: Contribution to journalArticle

Broughan, TA, Valenzuela, R, Escorcia, E, Secic, M & Vogt, DP 1994, 'Mouse antibody-coated lymphocytes during OKT3 therapy in liver transplantation', Clinical Transplantation, vol. 8, no. 5, pp. 488-491.
Broughan TA, Valenzuela R, Escorcia E, Secic M, Vogt DP. Mouse antibody-coated lymphocytes during OKT3 therapy in liver transplantation. Clinical Transplantation. 1994 Nov 11;8(5):488-491.
Broughan, T. A. ; Valenzuela, R. ; Escorcia, E. ; Secic, M. ; Vogt, D. P. / Mouse antibody-coated lymphocytes during OKT3 therapy in liver transplantation. In: Clinical Transplantation. 1994 ; Vol. 8, No. 5. pp. 488-491.
@article{4dcc3eb896494ca0aee7a0047c5bc27d,
title = "Mouse antibody-coated lymphocytes during OKT3 therapy in liver transplantation",
abstract = "Flow cytometry has been a technique in search of a use in transplantation. With each new monoclonal antibody, it has been hoped that the secrets of rejection would be unlocked. The usefulness of CD3+ T-lymphocyte counts to predict successful treatment of organ transplant rejection has been called into question. CD2+, CD3+, and mouse antibody-coated CD3+ lymphocytes were followed by flow cytometry in 44 liver transplant patients during OKT3 therapy for induction or rejection. CD3+ lymphocyte counts did not predict successful management of rejection by OKT3. When expressed as percentages of the total lymphocyte count, an increasing trend in CD2+ and mouse antibody-coated CD3+ lymphocytes after day 7 of OKT3 therapy portended persistent or recurrent rejection within 2 months of treatment. It is uncertain if the increasing population of mouse antibody-coated CD3 cells is due to an immune phenomen or decreased clearance by an ailing liver. Care should be taken when using CD3 lymphocyte counts as indicators of adequate OKT3 therapy in liver transplantation.",
keywords = "Flow cytometry, Liver transplantation, Monoclonal antibody, Rejection",
author = "Broughan, {T. A.} and R. Valenzuela and E. Escorcia and M. Secic and Vogt, {D. P.}",
year = "1994",
month = "11",
day = "11",
language = "English",
volume = "8",
pages = "488--491",
journal = "Clinical Transplantation",
issn = "0902-0063",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Mouse antibody-coated lymphocytes during OKT3 therapy in liver transplantation

AU - Broughan, T. A.

AU - Valenzuela, R.

AU - Escorcia, E.

AU - Secic, M.

AU - Vogt, D. P.

PY - 1994/11/11

Y1 - 1994/11/11

N2 - Flow cytometry has been a technique in search of a use in transplantation. With each new monoclonal antibody, it has been hoped that the secrets of rejection would be unlocked. The usefulness of CD3+ T-lymphocyte counts to predict successful treatment of organ transplant rejection has been called into question. CD2+, CD3+, and mouse antibody-coated CD3+ lymphocytes were followed by flow cytometry in 44 liver transplant patients during OKT3 therapy for induction or rejection. CD3+ lymphocyte counts did not predict successful management of rejection by OKT3. When expressed as percentages of the total lymphocyte count, an increasing trend in CD2+ and mouse antibody-coated CD3+ lymphocytes after day 7 of OKT3 therapy portended persistent or recurrent rejection within 2 months of treatment. It is uncertain if the increasing population of mouse antibody-coated CD3 cells is due to an immune phenomen or decreased clearance by an ailing liver. Care should be taken when using CD3 lymphocyte counts as indicators of adequate OKT3 therapy in liver transplantation.

AB - Flow cytometry has been a technique in search of a use in transplantation. With each new monoclonal antibody, it has been hoped that the secrets of rejection would be unlocked. The usefulness of CD3+ T-lymphocyte counts to predict successful treatment of organ transplant rejection has been called into question. CD2+, CD3+, and mouse antibody-coated CD3+ lymphocytes were followed by flow cytometry in 44 liver transplant patients during OKT3 therapy for induction or rejection. CD3+ lymphocyte counts did not predict successful management of rejection by OKT3. When expressed as percentages of the total lymphocyte count, an increasing trend in CD2+ and mouse antibody-coated CD3+ lymphocytes after day 7 of OKT3 therapy portended persistent or recurrent rejection within 2 months of treatment. It is uncertain if the increasing population of mouse antibody-coated CD3 cells is due to an immune phenomen or decreased clearance by an ailing liver. Care should be taken when using CD3 lymphocyte counts as indicators of adequate OKT3 therapy in liver transplantation.

KW - Flow cytometry

KW - Liver transplantation

KW - Monoclonal antibody

KW - Rejection

UR - http://www.scopus.com/inward/record.url?scp=0028110408&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028110408&partnerID=8YFLogxK

M3 - Article

VL - 8

SP - 488

EP - 491

JO - Clinical Transplantation

JF - Clinical Transplantation

SN - 0902-0063

IS - 5

ER -